HomeBUSINESS
BUSINESS

AZ’s Olaparib Filed for Breast Cancer in 2nd Submission
(Oct.24.2017)

AstraZeneca said on October 23 that it filed a new drug application in Japan for its PARP inhibitor olaparib for the treatment of unresectable or recurrent BRCA-mutated breast cancer, the second submission after one in ovarian cancer ...
(LOG IN FOR FULL STORY)

News Calendar